Macular Degeneration St. George Utah


UCSD links herbicide to liver disease

UC San Diego School of Medicine researchers report that exposure to glyphosate — the primary ingredient in Monsanto’s popular Roundup weed-killer — correlates to more severe cases of nonalcoholic fatty liver disease.

Published in Clinical Gastroenterology and Hepatology, the study examined glyphosate excretion in the urine samples of two patient groups — those with a diagnosis of nonalcoholic steatohepatitis (NASH), a nonalcoholic fatty liver disease, and those without. The results were significant: Regardless of age, race, body mass index, ethnicity or diabetes status, glyphosate residue was significantly higher in patients with NASH than it was in patients with a healthier liver.

“The increasing levels (of glyphosate) in people’s urine very much correlates to the consumption of Roundup-treated crops into our diet,” said Paul Mills, professor and chief in the Department of Family Medicine and Public Health at UCSD School of Medicine.

The findings, coupled with prior animal studies, said Mills, suggest a link between the use of commercial glyphosate in our food supply, which has increased significantly over the past 25 years, and the prevalence of NAFLD in the U.S., which too has been on the rise for two decades.

Next up for Mills is putting a group of patients on an all-organic diet and examining how an herbicide-free diet might affect biomarkers of liver disease.

New La Jolla networking group

Business Network International (BNI) — a franchised networking organization with about 233,000 members in 8,399 local chapters worldwide — has launched its second La Jolla chapter, BNI Ranch & Coast, led by Joy Bender, a real-estate agent with Compass.

“Our group is sincerely committed to helping one another, using each other’s services, and providing dynamic testimonials,” Bender said. “It’s taken us six months to get the group launched and our group should have $30,000 in closed business by the end of our first month.”

BNI Ranch & Coast meets 7 a.m. Tuesdays at The LOT, 7611 Fay Ave. Breakfast is $30. (760) 212-2717.

The other La Jolla BNI chapter, BNI of La Jolla, meets 6:45 a.m. Tuesdays at Congregational Church of La Jolla, 1216 Cave St.

UCSD pinpoints brain’s judgment center

Neurobiologists at the UC San Diego have located the brain area responsible for value decisions made based on past experiences.

According to their research — published in the latest issue of the journal Cell — data from tens of thousands of neurons revealed an area of the brain called the retrosplenial cortex (RSC), which was not previously known for value-based decision-making, a fundamental animal behavior that is impaired in neurological conditions ranging from schizophrenia to dementia and addiction. Its decisions include where we buy our morning coffee.

“When you have two coffee shops to choose from, no one is telling you which one to go to — you rely on the internal value in order to choose one over the other,” said senior author Takaki Komiyama, a neurosciences professor in UCSD’s Division of Biological Sciences and School of Medicine. “How the brain maintains this value information — and how it might be different in healthy and disease states — could be relevant in clinical applications.”

La Jollan earns honorary Ph.D.

La Jolla resident Mary Fair Berglund has been awarded an honorary doctorate of human letters by Oregon’s Pacific University, from which she graduated in 1958.

Berglund — executive vice president of a private asset and portolio management company since 1984 — is a trustee and treasurer of both the Charles Lee Powell Foundation and the ResMed Foundation, as well as chair of the Powell Foundation’s Investment Committee, which has funded more than $105 million in grants for engineering research at Stanford, Caltech, USC and UC San Diego.

Contributions from Berglund and her husband, Jim, have resulted in the addition of Berglund Hall to Pacific University’s Forest Grove Campus in 2007, the founding of the College of Business in 2013, and the Berglund Center, an on-campus incubator for students to develop and launch products and services ideas.

UCSD study has eye on macular regeneration

Using stem cells from six people, UC San Diego School of Medicine researchers recapitulated retinal cells in the lab. This “eye-in-a-dish” model allowed them to look for genetic variants that might contribute to age-related macular degeneration (AMD), one of the most common causes of vision loss in people over age 65.

Published in the latest issue of the journal Stem Cell Reports, the study revealed the importance of a specific variation in the VEGFA protein that affects expression of the VEGFA gene and is known for supporting new blood-vessel growth — a process that goes awry in AMD.

“We didn’t start with the VEGFA gene when we went looking for genetic causes of AMD,” said senior author Kelly Frazer, professor of pediatrics and director of the Institute for Genomic Medicine at UCSD School of Medicine. “But we were surprised to find that, with samples from just six people, this genetic variation clearly emerged as a causal factor.”

AMD involves the slow breakdown of cells that make up the macula, which is part of the retina, a region in the back of the eye that sends information to the brain.

— News Nuggets compiled by Corey Levitan from local reports

Lane closures, night work to finish slope restoration

With Memorial Day and the start of the summer construction moratorium just a few days away on May 27, the Torrey Pines Road Slope Restoration Project is in its final stages.

Although San Diego public information officers could not confirm that the project would be complete by the Memorial Day holiday, City Council member Barbara Bry’s field rep Mauricio Medina told the La Jolla Community Planning Association during its May 2 meeting: “The latest information I have is that they are aiming to finish by the end of this month” and that “we are trying to get the Public Works Department to wrap this up.” Should the project not be complete, work would suspend until the end of the summer construction moratorium (Labor Day, Sept. 2).

The work thus far has meant closures in the eastbound lanes of Torrey Pines Road, and some battles about whether to do some of the work at night. Through May 24, night work is scheduled 9 p.m. to 5 a.m. Monday-Thursday.

The project, located on the south side of Torrey Pines Road between Roseland Drive and Little Street, is a continuation of the Torrey Pines Road Corridor Project Phase II, which started last year, and will reconstruct a 350-foot section of earthen slope.

Ashley Mackin-Solomon



Source link


A health agency in France is warning that LED lights can not only disrupt your sleep but also damage your eyes.

These types of lights are used often in our very own homes. How are they affecting our health?

This new report comes from ANSES

, the French Agency for Food, Environmental and Occupational Health & Safety. They found new scientific evidence confirming the “phototoxic effects” of short-term exposures to high-intensity blue light. Now, phototoxicity is a condition where the eyes or skin have become overly sensitive to light. ANSES also found that chronic exposure to lower intensity sources can damage the retina in our eyes, and this can increase your risk of age-related macular degeneration. As for sleep, blue light can disturb your natural sleep rhythms because our eyes’ have blue light photoreceptors. So exposure to blue light at night can lead to a suppression of the hormone melatonin, which we all need to help us sleep.

What is age-related macular degeneration?

Unfortunately, age-related macular degeneration is an eye condition that can lead to vision loss, especially for folks who are 50 and older. And it happens because of damage to a small area in the retina that is responsible for sharp vision, and that’s the macula. Unfortunately, there is no known cure for macular degeneration. And older adults are not the only ones to be concerned — children cannot fully filter blue light because their eyes are still developing, so they need to be extra careful due to the potential harms of blue light.

What about anti-blue light sunglasses, do they work?

Well the report said protection via anti-blue light screens, sunglasses and filters have not been proven. In fact, another study back in 2017 investigated these types of products and also found that there was not enough high-quality evidence to support their use. So I would not recommend them. But for the most part, sunglasses are designed to block out ultraviolet light. So ones with a yellow tint could possibly be useful in lowering how much blue light gets to your eyes. Also, I suggest you limit the use of white and cold blue light in your home as this type was found to be more harmful. Whereas “warm white” LED lighting was found to be better as it has weaker phototoxicity risks.





Source link


Retinal biologics market value surpassed US$ 14.6 billion in 2018 and projected to grow at 10.7% y-o-y in 2019, as per a new FMI study. The projected growth of the market can be attributed to,

Increasing prevalence of diabetic eye diseases and age-related macular degeneration (AMD)

Significant R&D investments engaged in developing biologics for infectious and non-infectious retinal diseases

Growing application of specific biologic molecules as a promising drug target

Development of gene therapy as retinal biologics in the wake of large number of monogenic retinal disorders

“Higher specificity of retinal biologics as compared to other traditional therapies has escalated R&D efforts in the retinal drug delivery field. Rising burden of diseases as well as treatment on the back of ageing population and spread of diabetes epidemic have increased efforts in finding the cure of untreatable diseases. Greater strides to develop long-acting therapeutics in a bid to reduce disease burden is set to augur well for the retinal biologics market and generation of US$ 16.2 billion market value is projected in 2019,” says FMI report.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8663 

Promising Treatment of VEGF-A Antagonist Drug Translates to Hefty Revenue Generation

The FMI study estimates that adoption of VEGF-A antagonist class of drugs remains higher as compared to TNF-? inhibitor. In 2018, VEGF-A antagonist drugs witnessed significant penetration while accounting for a hefty 93% revenues of the retinal biologics market. Significant advances in developing biologics for VEGF-A antagonist therapy and their delivery to posterior ocular tissues are underway.

Ubiquitous acceptance of VEGF-A antagonist therapy has led manufacturers to invest in the development of retinal biologics in a similar area. For instance, Eylea by Regeneron and Lucentis by Roche are VEGF-A antagonist drugs available in the market.

The study finds that despite lower revenues, penetration of TNF-? inhibitor drugs is likely to increase at a rapid pace in the coming years. In 2019, annual revenues of TNF-? inhibitor drug class is expected to grow at an impressive rate of 11.6%.

Retinal Biologics Find Prominent Use in Macular Degeneration Treatment

The study opines that over 35% of the retinal biologics revenues were consolidated in the treatment of macular degeneration. Highest revenue growth of 12.3% is also expected in macular degeneration as compared to other indications where retinal biologics are used in 2019.

Macular degeneration (MD) remains the leading cause of vision loss wherein it affects over 10 million Americans, the prevalence is higher than the combined incidences of cataract and glaucoma, as per the American Macular Degeneration Foundation (AMDF). As macular degeneration mainly affect people of age 50 years or more, with the ageing population, the prevalence of MD continues to rise despite improved treatment options.

Diabetic retinopathy and diabetic macular edema treatments also significantly include retinal biologics in therapy. FMI shows that collectively both the disorders accounted for over 43% of the retinal biologics market revenues in 2018. Annual revenue growth in these two disorders is estimated to remain above 10% in 2019. Increasing incidences of diabetes complications on the back of growing epidemic of diabetes will continue to increase cases of diabetic retinopathy and diabetic macular edema, thereby generating demand for retinal biologics in the coming years.

Retinal Biologics Distribution in Specialty Clinics and Hospitals Prominent

Manufacturers in the retinal biologics market distribute the products through institutional and retail distribution channels. The FMI study finds that institutional sales will garner higher revenues in the retinal biologics market wherein retinal biologics are distributed in specialty clinics and hospitals. Sales in hospitals accounted for over 35% of the market revenues in 2018.

The study estimates that retail sales of retinal biologics will garner similar revenues as that of hospitals and grow at 11.9% in 2019. Retail distribution occurs through retail pharmacies and mail order pharmacies of which retail pharmacies will register higher revenues as compared to its counterparts in the coming years.

Request Methodology of this Report @ https://www.futuremarketinsights.com/askus/rep-gb-8663 

Penetration in North America Higher, APEJ’s Attractiveness to Increase

North America continues to hold leading revenues in the retinal biologics market. According to FMI valuation, North America held over 46% of the global retinal biologics market revenues in 2018. Revenues in North America are expected to grow at 10.4% y-o-y in 2019 on the back of increasing prevalence of retinal disorders, steady growth of the healthcare infrastructure and favorable reimbursement scenario.

Europe garnered nearly one-fourth revenues in the retinal biologics market, wherein a bulk of demand penetration was observed in Western European countries such as Germany, the UK, France, Italy, Spain and others. The attractiveness of the APEJ retinal biologics market is expected to rise at the rate of 11% in 2019, wherein China and India remain the most lucrative markets.



Source link


During New York’s Design Week, when the world’s leading architects and designers previewed new flooring with designs based on fractals, University of Oregon physics professor Richard Taylor was on hand to explain the science behind it.

Designed for Mohawk Group by the renowned Austrian firm 13&9 in collaboration with Taylor’s company, Fractals Research, the “Relaxing Floors” system translates stress-reducing fractal patterns into calming visuals for the built environment.

Designers Anastasija and Martin Lesjak contacted Taylor about 18 months ago to see if he would be willing to help them revolutionize flooring intended for workplaces, hotels and schools as well as venues where many people feel anxious, such as airports and hospitals.

“We wanted to give our eyes a break from the digital world and deliver the essence of nature to enclosed spaces, but we needed to be certain that our designs are based on scientific research,” Anastasija Lesjak said. “That’s where Professor Richard Taylor, the leading expert on fractals, has been invaluable. Add to this Mohawk Group’s commitment to using sustainable materials, and you have the next generation of flooring solutions.”

“I had no idea how famous Ana and Martin were,” said Taylor, who heads the UO physics department. “I was just extremely excited to have a chance to apply what we’ve learned about fractals to their project because the World Health Organization describes stress as the leading health epidemic of this century.”

Scientifically informed design

Taylor hopes the partnership with Mohawk Group and 13&9 will allow UO scientists to evaluate potential public health benefits of fractal flooring. He leads an interdisciplinary research network that investigates the positive physiological changes that occur when people look at the most common form of fractals found in nature.

Their findings to date, published in numerous peer-reviewed scientific journals, indicate that merely looking at such patterns can reduce stress by as much as 60 percent. More than $300 billion are spent annually in the United States on stress-induced illnesses and disorders.

“One of the best pieces of news from our psychology research is that you do not need to be exposed to fractal patterns long to get the positive effect,” Taylor said. “You don’t even need to stare directly at them. This means you can be walking along an airport corridor, not even paying attention to what’s under your feet, and the patterns on this carpeting may help reduce your level of stress by up to 60 percent.”

Team effort unites Austria, UO

In addition to the Lesjaks, the Austrian team includes Sabrina Stadelober and Luis Lee. Two of Taylor’s graduate students, Julian Smith and Conor Rowland, also have been serving as consultants on the Oregon side.

“Julian and Conor are fundamentally at the center of all the pattern creation action,” Taylor said. The Oregon team’s software-generated fractals are based on parameters that previous psychology experiments indicate reduce stress.

“We uploaded these fractal patterns to the 13&9 design team in Austria so they could adapt them according to their design vision and send back to us for analysis.” Taylor said. “Our next challenge was to adapt their designs to be sure they would meet the required parameters, no matter how randomly the blocks of carpeting are laid out when they are installed in huge venues.”

The full team met at the UO in March to lay out sample carpet panels in random patterns so Taylor could confirm that the stress reducing aspect of the design remains constant.

Foraging birds and bionic eyes

Two of the flooring styles mimic the eye movements that take place as we view natural scenery, Taylor said.

“Our eyes follow a pattern that is much like the flight paths of foraging birds,” he said. “My team developed software to create a fractal pattern similar to that of a flying bird releasing seeds that will grow into trees and plants.”

Another style was inspired by UO studies of fractal-based electronics – notably, the project to develop a bionic eye to restore vision destroyed by retinal diseases such as macular degeneration.

“The fractal branching of the eye’s neurons was the starting point for this design,” Taylor said. “We transformed these neuron formations into outline patterns using our research on stress-reductive fractals.”

Jackie Dettmar, Mohawk Group’s vice president of design and product development, said the project could have a “groundbreaking impact” on the built environment.

“This whole collaboration has been an amazing experience,” she said. “Understanding the science behind biophilic design is part of our commitment to diving deeper into creating environments for decompressing and getting away from that overload of technology that we’re living with every day.”

Next stop: NeoCon

So far, In addition to winning a Metropolis Likes @ NYCxDESIGN award, ”Relaxing Floors” was a finalist for the Interior Design NYCxDESIGN award for contract flooring.

Based in Georgia, Mohawk Group is the world’s leading producer and distributor of commercial flooring. The Relaxing Floors system will officially debut June 10-12 at Chicago’s NeoCon, considered the event of the year for the commercial design industry.

—By Melody Ward Leslie, University Communications



Source link


ALAMEDA, Calif.–(BUSINESS WIRE)–

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has appointed Chase C. Leavitt as BioTime’s General Counsel and Corporate Secretary.

“We’re extremely fortunate to have Chase join us and bring his extensive public company experience as well as a strong track record to the role of general counsel,” stated Brian M. Culley, Chief Executive Officer of BioTime. “Chase’s diverse industry experience including SEC compliance, corporate governance, strategic transactions and mergers and acquisitions will be instrumental as BioTime continues to execute on its clinical and operational plans.”

Prior to joining BioTime, Mr. Leavitt served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences-focused investment company, and its affiliate Odonate Therapeutics, Inc., a publicly traded pharmaceutical company, from June 2018 to May 2019. From May 2017 to May 2018, Mr. Leavitt served as the Deputy General Counsel of Switch, Inc., a publicly traded technology company, and previously served as its Associate General Counsel from July 2014 to May 2017. From 2007 to 2014, Mr. Leavitt was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and capital markets, serving life sciences and technology companies. Mr. Leavitt received a B.S. in Business Administration and a J.D. from the University of Southern California and is admitted to practice law by the State Bar of California.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company developing new cellular therapies for unmet medical needs. BioTime’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform BioTime develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury, or administered as a means of helping the body mount an effective immune response to cancer. BioTime’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.biotimeinc.com or follow the Company on Twitter @BioTimeBTX.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190522005219/en/





Source link


The report titled “Global Age Related Macular Degeneration (AMD) Market” gives a proper understanding of global Age Related Macular Degeneration (AMD) industry. Furthermore it also cover-up forecast and analysis for Age Related Macular Degeneration (AMD) market on the global and regional level. The report analyses Age Related Macular Degeneration (AMD) market on basis of its attractiveness and investment feasibility. It also presents a proper description of every section and emerging industry trends. This will allow the readers to target Age Related Macular Degeneration (AMD) market product specifications, current competitive players in Age Related Macular Degeneration (AMD) market and the market revenue with profitability. Global Industry Analyze Age Related Macular Degeneration (AMD) Market by its type, competitive players, regions, and applications of Age Related Macular Degeneration (AMD) market, forecast up to 2025. This report analyses the scope of Age Related Macular Degeneration (AMD) market. This can be achieved by using Age Related Macular Degeneration (AMD) previous historical data, analysing qualitative insights in detail, provable projections about global Age Related Macular Degeneration (AMD) market size. The projections showed in this Age Related Macular Degeneration (AMD) report are taken from previously proved research methodologies and hypothesis. By performing such projections, the Age Related Macular Degeneration (AMD) market research report serves as a storehouse of analysis, data, and information for every aspect of the Age Related Macular Degeneration (AMD) market. Considering the geographic area, Age Related Macular Degeneration (AMD) market is divided into various regions like Asia-Pacific, South America, Middle-East a and Africa, and Europe.

Request For Free Sample Pdf Report @ http://marketdesk.us/report/global-age-related-macular-degeneration-amd-market-pr/84390/#requestForSample

Global Age Related Macular Degeneration (AMD) Market(2019-2025) Key Company’s Coverage(Sales Revenue, Price, Gross Margin, Main Products etc):

Bayer, F. HoffmannLa Roche, Regeneron, Novartis, Valeant, Pfizer and More…

Click Here For Inquiry:- http://marketdesk.us/report/global-age-related-macular-degeneration-amd-market-pr/84390/#inquiry 

Global Age Related Macular Degeneration (AMD) Market(2019-2025) Region Coverage (Regional Output, Demand & Forecast by Countries etc.):

Asia-Pacific, South America, North America, Europe, Middle East & Africa

Market Segment by Product Type:

Wet AMD, Dry AMD and More…

Market Segment by Application:

Men, Woman and More…

Fundamental Specifications Included In Global Age Related Macular Degeneration (AMD) Market Research Report Are As Follows:

The First Section of the Age Related Macular Degeneration (AMD) market research report highlights industry overview, upstream and downstream market segmentation, and the cost analysis.

The Second and Third Section gives a close view of the enterprise environment, Age Related Macular Degeneration (AMD) market by type along with segment overview, market forecast, and market size.

> Next two Section list the top manufacturers and companies involved in the Age Related Macular Degeneration (AMD) market and competitive situations of these market players.

The Sixth Section includes Age Related Macular Degeneration (AMD) demand situation, market demand, demand comparison according to geographical regions, and demand forecast.

> Seventh and Eighth Section highlights region operation, price/cost of the product, product margin, by region and regional forecast, value chain, and sales channel.

The Last Section of the Age Related Macular Degeneration (AMD) market report displays research findings and conclusion.

Get Our Trending Research Reports Here:

Purchase Report Here:

https://marketdesk.us/purchase-report/?reportId=84390&licenseType=single_user&action=Purchase+Report



Source link


The Mediterranean diet has been called the healthiest in the world, and has been named the easiest to follow by US News & World Report. In fact, out of eight categories, it was #1 in six of them, including Best Diets Overall and Easiest Diets to Follow (1). It can be followed by an entire household, including children; dieters can find things to eat at restaurants and friends’ houses. Unlike many diets, it’s not intended to be short-term or to create immediate drastic changes: The Mediterranean diet is the definition of a lifestyle, based off the actual lifestyles of those living around the Mediterranean sea. It doesn’t have strict guidelines like Paleo; cheating doesn’t result in negative consequences, such as blood vessel damage, like it can on Keto; and unlike Atkins, there isn’t an exit strategy—you’re not supposed to exit. If a customer is looking to lose weight fast, this might not be the diet for them (2). If they’re looking for easy, long-term health, though, the Mediterranean diet is ideal. This is a diet that is known to be great for cardiovascular health, and other studies are finding that that’s far from the end of it.

For the cardiovascular benefits, a meta-analysis based on 26 studies found that the Mediterranean diet decreased risk of CVD by 20-25% (3). The Mayo Clinic notes some side benefits—specifically, associations with a reduced incidence of cancer, Parkinson’s, and Alzheimer’s disease (4). A study published in Neurology looked at MRI scans and dietary information from 674 elderly adults without dementia, and found that higher adherence to a Mediterranean diet was associated with larger brain volume, gray matter volume, and white matter volume, and higher fish intake was associated with a larger average cortical thickness (5). The difference in brain atrophy between those with low adherence to the diet and those with high adherence was the equivalent of five years of aging. Yet another study, this one published in American Academy of Ophthalmology, looked at 4,446 participants from a study based in the Netherlands and 550 adults from a study based in France (6). By pooling the data, researchers found that those with a high adherence to the diet had a 41% reduced risk for advanced age-related macular degeneration. Jery Cochern, founder and president of R&D at Pure Essence, Las Vegas, NV, notes that it’s a good choice for digestive health: “The Mediterranean diet is characterized by minimizing meats and focusing on fruits and vegetables, food choices that reduce gut inflammation and promote a healthy digestive tract microbiome.” He adds that “every holist since Hippocrates has seen the digestive tract as the beginning of all health or disease,” making it likely that many of Mediterranean’s benefits arise from this initial perk.

For parents used to cooking separate meals for themselves and children, this diet is a lifesaver. Not only can Mediterranean foods be kid-friendly, but a study by Rosario Ferrer-Cascales et al. performed on 527 Spanish adolescents found that adherence to Mediterranean led to higher levels of subjective happiness and health-related quality of life (7). Those parents with very young children, who might be a little pickier, can turn to cookbooks like Gourmet Mediterranean Cuisine for Children by Aslihan Koruyan Sabanci for suggestions for both children’s meals and adult’s meals that will appeal to children. Sabanci’s book has meal suggestions for children of all ages, starting from the moment parents begin to wean them off milk.

Putting It On the Dinner Table
The Mediterranean diet doesn’t have strict do- and don’t-eat lists; It’s based on the eating habits of those living in Spain, Southern Italy, Turkey, and Greece—entirely different countries with access to different foods. There are, however, some basics: fresh vegetables, fruits, nuts, legumes, seafood, whole grains, and olive oil are all staples of the diet. Red meat should be consumed rarely and sparingly; poultry can be eaten a little more often. And, of course, a glass of wine with dinner is encouraged.

Cochern points out that, in terms of general macronutrient intake, it’s around the same as a Western Diet: “The typical breakdown is 50%-60% of calories from carbs, 15% to 20% from proteins and 35%-45% from fats.” These basics can serve as a loose guideline for those looking for more structure, and those who are switching to this diet from one with a very different breakdown (like Keto) may want to consider enzymes, like those from Pure Essence, until their bodies begin making the necessary enzymes again.

Fortunately, all of these foods can be found organic and functional. But note that olive oil is no stranger to mislabeling—Forbes reported that a large percentage of olive oil is, at best, not extra virgin (8). Buy from a small farm or co-op, or a reputable company. Carlson Nutritional Supplements sells extra virgin olive oil from Crete, Greece—and it comes blended with sustainably-sourced fish oil, for that extra heart health hit. Carlson sells it in packets, too, so those who hate soggy salads can package their salad for work and add olive oil right before eating—and, hopefully, right after the vinegar, so that their salad can absorb the vinegar before the oil makes it waterproof.

Wine can be organic, too—Frey Vineyards has been selling organic, gluten-free wine without added sulfites since 1980, and was the first winery in the U.S. to be certified Biodynamic. Besides just being free of toxic chemicals, Frey’s website cites a study from UC Davis, California, showing that organic fruits and berries have up to 58% higher antioxidants than non-organic (9).

This might all expose a problem for busy customers: There’s not much to eat on a Mediterranean diet that’s quick-and-easy. Jumpstart them with some slow cooker recipes: Maybe ease them in with garlic parmesan chicken and potatoes, found on DamnDelicious.net, with a prep time of 10 minutes and a cook time of eight hours—the ideal workday dinner (10). Similarly, the Lemon Basil Ratatouille found on Wholesomelicious.com has 10 minutes of prep time and 5 minutes of cook time, along with a variety of vegetables (11). That particular recipe has a helpful note at the end: When working with eggplant, slice it, sprinkle on some sea salt, and let it sit. Soak up whatever liquid comes out, and the eggplant won’t come out with a bitter taste.

All else fails—go back to that Gourmet Mediterranean Cuisine for Children cookbook by Sabanci. It says children, but adults can appreciate Zucchini Au Gratin or Pearly Pasta with Buffalo Mozzarella and Fresh Basil just as much as any kid, and with 154 recipes, there’s plenty that’ll work for a weeknight. And while the emphasis with Mediterranean is on fresh foods, there are a few convenience foods that can be found pre-packaged—and organic—like hummus. Try Tribe: organic, non-GMO, with no artificial preservatives, and in a variety of flavors. For other pre-packaged Mediterranean foods, look into Cedar’s. Tzatziki, salads, pita chips, dips, and salsa—Non-GMO Project Verified, USDA Organic, and certified gluten-free. Cedar’s has snack packs, too, perfect for school or work lunches.

Customizing with Supplements
In spite of all the freedom allowed on Mediterranean, there are places it can fall short. Those on this diet might want to take stock of what they’re cutting out of it, and consider some of the following supplements:

Resveratrol. One major perk is that wine is worked into and encouraged in Mediterranean, but there are plenty of people who can’t or don’t drink. If your customer isn’t looking to make wine part of their lifestyle, they might want to start taking a resveratrol supplement. It’s a polyphenol: found in red grapes, peanuts, and berries, it’s thought to act like an antioxidant (12). It can also help prevent insulin resistance (12).

Vitamin B12. The dietary source for this vitamin comes from animals, and while it can be found in feta cheese, sardines, and eggs, most people get their dietary intake from red meat like lamb or beef. If your customers decrease or nix their red meat intake, this is an important supplement to consider. It’s used in the production of energy, and it benefits mood, memory, digestion, and hormonal balance, among others, making it invaluable (13).

Vitamin D. The Mediterranean is a sunny area. Depending on where you and your customers are located—or depending on whether or not your customers get plenty of time outdoors—it’s worth it to invest in this supplement, which is necessary for the absorption of calcium and phosphorous and helps maintain proper bone structure (14).

Omega-3. This one might come as a surprise to your customers—omegas are half the point of eating seafood. But if the dieter in question is starting this diet expressly for the sake of enjoying its cardioprotective benefits, they might want to know that, according to one study, achieving a cardioprotective level of omega-3 in the blood required both three fish meals per week and supplement usage (15). This is also a worthwhile supplement for those who just don’t like fatty fish.

Calcium. One study found that Westerners on a Mediterranean diet didn’t get the amount of calcium called for by federal guidelines (16). This doesn’t necessarily need to be in supplement form—that same study found that adding more cheese and dairy into the diet helped people meet their calcium requirements without taking away from any of the benefits Mediterranean has to offer. That said, your lactose intolerant customers might not have that option, and might appreciate the heads up.

Enzymes. Cochern points out that “no diet is any better than how well its digested.” Mediterranean, of course, provides a variety of fruits and vegetables, as well as a healthy amount and ratio of omega-3 and -6 fatty acids. “But, again,” Cochern says, “These things must be digested. To whatever degree they’re not, the nutrients they provide are wasted. So those with frequent digestive complaints should ensure efficient digestion by using exogenous enzymes.”

The Mediterranean diet is, in fact, all it’s cracked up to be—and then some. But remind your customers that it’s a lifestyle, not a diet. Encourage exercise; If you happen to host yoga classes or something similar, this is a great time to pitch them, because exercise is integral to the Mediterranean lifestyle. If you don’t, or if your customers are wary about the time and commitment exercise takes, refer them to a recent blog post on NaomiWhittel.com by Naomi Whittel, author of Glow15, on the benefits of a 15-minute post-meal walk (17)—but whatever works for them, they really should do it; the diet includes the assumption of exercise. This lifestyle is so customizable that, if your customers don’t keep an eye on it, they could customize benefits right out of it. WF



Source link


Eye research charity, Fight for Sight, is funding the development of an ‘organ-on-chip’ that for the first time will be used to help investigate glaucoma, a leading cause of blindness.

Dr Darryl Overby and Dr Sam Au from Imperial College London, in collaboration with Massachusetts Institute of Technology (MIT) and Duke University, will build upon the latest bioengineering technology to develop a new device that mimics the flow of fluid (or ‘aqueous humor’) as it drains from the eye.

The matchbox sized ‘organ on a chip’ is made from a special gel that contains channels the width of a match that are surrounded by human eye cells. Essentially, an entire laboratory can fit on the device, running several experiments in parallel on the same chip.

Researchers will use the device to better understand how eye pressure is controlled and will design drugs to target the pressure-controlling mechanisms in the eye. Using the new device researchers will be able to manipulate specific cells and examine the effects on flow of fluid from the eye. The ultimate aim is to improve our understanding of fluid flow to lower the increased eye pressure that people experience in glaucoma, which results in damage to the optic nerve and sight loss.

This technology has the potential to be applied to research on a wide range of other eye conditions such as retinal degeneration, macular degeneration and diabetic retinopathy.

Glaucoma is associated with increased pressure in the eye, resulting from a failure in the eye fluid draining away. However, it is not fully understood how this process is controlled which means current drugs are unable to precisely target the causes.

Dr Neil Ebenezer, Director of Research, Policy and Innovation at Fight for Sight, said:

We’re excited to fund the development of a bioengineered ‘organ on a chip’ which can recreate a whole lab on a device the size of a matchbox – this opens the door to testing aspects of glaucoma and other eye disease that have previously been difficult to investigate and could offer solutions for this leading cause of sight loss.”

Lead Researcher, Dr Darryl Overby from Imperial College London, said:

Organ-on-chip technologies provide the unique opportunity to probe organ and tissue-level functions without using animal models. By applying organ-on-chip approaches to the trabecular meshwork, which is the primary drainage route from the eye, we can investigate directly how this tissue regulates eye pressure. This will ultimately allow us to develop better drugs that more effectively lower eye pressure and prevent blindness in glaucoma. We are thankful to Fight for Sight and for the generosity of their donors to be able to work on this exciting project.”

The £100,000 awarded by the charity, Fight for Sight will support the three year project.

Glaucoma is the name for a group of eye conditions that causes sight loss because of damage to the optic nerve (the nerve that connects the eyes to the brain).





Source link


LONDON, May 22, 2019 /PRNewswire/ — Global Ophthalmic Surgical Instruments Market by Product (Cataract Surgery Devices, Glaucoma Surgery Devices, Refractive Surgery Devices, Vitreoretinal Surgery Devices, Ophthalmic Microscopes and Ophthalmic Surgical Accessories), by End User (Hospitals, Specialty Clinics & Ambulatory Surgery Centers and other End User), Global Opportunity Analysis and Industry Forecast

Market Definition
• Ophthalmology is a branch of medical sciences that deals with the anatomical and physiological study of eyes such as function, structure and various diseases or disorders related to eyes. The Ophthalmic Surgical Instruments are used for the treatment of ophthalmic disorders such as glaucoma, cataract, refractive surgery, vitreoretinal surgery and others.
• Ophthalmic Surgical Instruments have gained traction in the past decades due to high prevalence of various ophthalmic diseases such as glaucoma, cataract, and other vision related issues supplemented by the growing ageing population across the globe.

Market Overview and Trends

• Minimally invasive or micro invasive glaucoma surgery (MIGS) devices, the novel age of glaucoma surgery has emerged out to be the most lucrative segment in the market owing to the safer and quick recovery time of the surgery.
• Ophthalmology surgical devices are used in retinal, refractive, cataract and glaucoma surgeries and for the diagnosis and effective treatment of eye diseases. These devices include ophthalmic viscoelastic devices (OVDs), intraocular lenses (IOLs), glaucoma drainage systems, excimer laser systems, femtosecond laser solutions, and consumables.
• High unmet needs especially for refractive surgeries due to the large number of patients with short-sightedness or myopia is fueling the market growth. For instance, according to a report ‘Ophthalmology’ journal, about 30% of the population is myopic or short-sighted currently worldwide and is projected to increase to 50% of the population i.e. around 5 billion by 2050 globally.
• The rapid rise in geriatric population and increasing eye disorders provides an opportunity to manufacture novel eye equipment, which opens new avenues in the industry.

Download samples here:

https://www.visiongain.com/report/global-ophthalmic-surgical-instruments-market-2019-2029/#download_sampe_div 

Market Dynamics:

Factors Influencing the Market Growth:
• Rapid rise in the geriatric population across the globe.
• Increasing prevalence of eye diseases such as glaucoma, cataract and Age-Related Macular Degeneration (AMD), obesity and diabetes among others.
• Technological Advancements in Ophthalmic surgical Devices for enhanced treatment.
• Rising government initiatives to prevent visual impairment globally.

Factors Restraining the Market Growth:
• High cost of ophthalmic surgical devices.
• Unclear reimbursement scenario for ophthalmic surgical procedures.

To find out more about this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-ophthalmic-surgical-instruments-market-2019-2029

Market Segmentation 2019-2029:

Product

• Cataract Surgery Devices Market, 2019-2029
• Intraocular Lenses
– Standard Intraocular Lenses
– Premium Intraocular Lenses
• Ophthalmic Viscoelastic Devices
– Cohesive Ovds
– Dispersive Ovds
– Combinational Ovds
• Phacoemulsification Devices
• Cataract Surgery Instruments and Kits
• Cataract Surgery Lasers
• IOL Injectors

• Glaucoma Surgery Devices Market, 2019-2029
• Glaucoma Drainage Devices
• Microinvasive Glaucoma Surgery Devices
• Glaucoma Laser Systems
• Glaucoma Surgery Instruments and Kits

• Refractive Surgery Devices Market, 2019-2029
• Femtosecond Lasers
• Excimer Lasers
• Refractive Surgery Instruments and Kits
• Other Refractive Surgery Lasers

• Vitreoretinal Surgery Devices Market, 2019-2029
• Vitreoretinal Packs
• Vitrectomy Machines
• Photocoagulation Lasers
• Vitreoretinal Surgery Instruments and Kits
• Illumination Devices
• Vitrectomy Probes

• Ophthalmic Microscopes Market, 2019-2029

• Ophthalmic Surgical Accessories Market, 2019-2029
• Ophthalmic Forceps
• Ophthalmic Spatulas
• Ophthalmic Tips and Handles
• Ophthalmic Scissors
• Macular Lenses
• Other Ophthalmic Accessories

End User
• Hospitals Market, 2019-2029
• Specialty Clinics and Ambulatory Surgery Centers Market, 2019-2029
• Other End Users Market, 2019-2029

Geographic breakdown
Focused regional forecasts and analysis explore the future opportunities:

• North America Market, 2019-2029
• U.S. Market, 2019-2029
• Canada Market, 2019-2029
• Mexico Market, 2019-2029
• Rest of North America Market, 2019-2029

• Europe Market, 2019-2029
• Germany Market, 2019-2029
• UK Market, 2019-2029
France Market, 2019-2029
• Spain Market, 2019-2029
• Italy Market, 2019-2029
• Rest of Europe Market, 2019-2029

• Asia-Pacific Market, 2019-2029
China Market, 2019-2029
• Japan Market, 2019-2029
India Market, 2019-2029
• Australia Market, 2019-2029
• Malaysia Market, 2019-2029
• Rest of Asia Pacific Market, 2019-2029

• LAMEA Market, 2019-2029
• Brazil Market, 2019-2029
Argentina Market, 2019-2029
• Turkey Market, 2019-2029
• South Africa Market, 2019-2029
• Rest of LAMEA Market, 2019-2029

Competitive Analysis:
• There are many companies operating in the market, however, number of players are entering in the market by developing more standardized and cost effective products.
• Companies are strategically expanding their global presence and offering improved products across various sectors.

Major Market Players:
• Essilor, Alcon, Johnson & Johnson Vision Care, Bausch + Lomb, Haag-Streit, TOPCON, Carl Zeiss Meditec, NIDEK, STAAR Surgical, HOYA, Novartis AG and Ziemer Ophthalmic Systems.

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

Abbott Laboratories, Inc.
Accutome
Acuity Pro
AJL Ophthalmic
Albert Heiss GmbH & Co
Alcon
Alcon Inc.
Amcon Business Products
American Surgical Instruments Company (ASICO)
Appasamy Associates
Appasamy Associates
Aurolab, Inc
Bausch + Lomb
Bausch + Lomb
Beaver Visitec Inc (BVI)
Belrose Refracting Equipment Co
BV
Carl Zeiss Meditec AG
CooperVision AG
Crescent Ophthalmic Instruments Co
DORC (Dutch Ophthalmic Research Center) International
Duckworth & Kent Ltd
E Janach
Eagle Labs
Ellex Medical Lasers
EMS / VSI
Essilor International S.A.
EyeKon Medical
Eyeonics
EyeQuip
FCI Ophthalmics
First Insight Corporation
Foresight International
Frimen Inc
Geuder AG
Glaukos Corporation
GMP Cos.
Gulden Ophthalmics
HAAG-Streit Holding AG
Heidelberg Engineering
Heidelberg Engineering Inc.
HEINE Optotechnik
Hoya Corporation
Hurricane Medical
IBEX EYE
Inami & Co., Ltd.
Instruments for Vision
Iridex
Japan Ophthalmic Instruments Association
John Weiss International
Johnson & Johnson
KAI Industries
Katalyst Surgical LLC
Katena Products, Inc
Kirwan Surgical Products, Inc
Kowa Company, Ltd.
Lombart Instruments
Lumenis
Luneau Technology Group
Luneau Technology group
LUXOTTICA GROUP
MANI, Inc
Marco Ophthalmic, Inc.
Medicel AG
Mediphacos Ltda
Meyco
MicroSurgical Technology
MicroVision
Moria
Nanjing OPT Optical Machinery Co.,Ltd.
New World Medical
Nidek Co., Ltd.
Norwood Abbey
Novartis AG
NOXINDIA CORPORATION
Oasis Medical, Inc
Ocular Instruments, Inc.
Oculus, Inc.
Ophthalmic Brokers
Pacific Ophthalmic Supply
Peregrine Surgical Ltd
Quantel Medical
Refocus Group
Reichert Technologies
Rhein Medical, Inc
Ridex Corporation
Rightway Optical Co.,Ltd
Rumex International
Shin-Nippon
Sightpath Medical
Sonomed Escalon
STAAR Surgical
Stereo Optical Co, Inc.
Surgical Specialties
Surgistar
Synemed, Inc.
TelScreen
Tomey
Topcon Corporation
U.S. Ophthalmic
Unique Technologies, Inc (UTI)
Unitech Vision
Valeant Pharmaceuticals International, Inc.
Veatch Ophthalmic Instruments
VisionCare, Inc.
Visionix Rus
Vitreq
Welch-Allyn
Woodlyn, Inc.
Ziemer Ophthalmic Systems AG

To discuss this report please e-mail Sara Peerun on sara.peerun@visiongain.com

View original content:http://www.prnewswire.com/news-releases/visiongain-publishes-global-ophthalmic-surgical-instruments-market-2019-2029-report-300853192.html



Source link


In this report, the United States Juvenile Macular Degeneration Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. United States Juvenile Macular Degeneration Treatment market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/united-states-juvenile-macular-degeneration-treatment-market-report-2018

Crystal Market Reports

In this report, the United States Juvenile Macular Degeneration Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Juvenile Macular Degeneration Treatment in these regions, from 2013 to 2025 (forecast).

United States Juvenile Macular Degeneration Treatment market competition by top manufacturers/players, with Juvenile Macular Degeneration Treatment sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Acucela Inc.
Alkeus Pharmaceuticals Inc
Astellas Pharma Inc
Copernicus Therapeutics Inc
Grupo Ferrer Internacional SA
Iris Pharma
Sanofi

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Avacincaptad Pegol Sodium
Echothiophate Iodide
Emixustat Hydrochloride
FAB-111
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Clinic
Hospital
Homecare

Browse full research report at https://www.crystalmarketreport.com/united-states-juvenile-macular-degeneration-treatment-market-report-2018

Reasons to Buy This Research Report

  • Complete access to United States Juvenile Macular Degeneration Treatment market size, growth rate and forecast to 2025
  • In-depth quantitative information on key regional United States Juvenile Macular Degeneration Treatment markets including North America, Europe, MEA and Asia Pacific
  • United States Juvenile Macular Degeneration Treatment Market estimates and forecasts for key products/applications on a regional basis
  • Facility to obtain country level information for complete United States Juvenile Macular Degeneration Treatment market segmentation
  • Key trends, drivers and restraints for global United States Juvenile Macular Degeneration Treatment market
  • Challenges to market growth for United States Juvenile Macular Degeneration Treatment manufacturers
  • Key market opportunities of United States Juvenile Macular Degeneration Treatment Industry

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Address: 90 State Street
Suite 700 Albany
New York 12207
Email: [email protected]
Web: https://www.crystalmarketreport.com


Post Views:
4



Source link